| Autor: |
Dayna Telken, Nael Haddad, Victor Arce Gutierrez, Donald Tschirhart, Yasmin Alishahi |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Galician Medical Journal, Vol 30, Iss 4 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2414-1518 |
| DOI: |
10.21802/e-GMJ2023-A01 |
| Popis: |
Immune checkpoint inhibitors are an increasingly utilized class of medications in oncology. Significant adverse effects have been reported, including hepatitis which mostly occurs early after initiating treatment. We present a case of a 78-year-old male with past medical history of recurrent sinusoidal mucosal malignant melanoma on pembrolizumab for three years that presented with painless jaundice of 72-hour duration. Laboratory evaluation demonstrated alkaline phosphatase at 1780 IU/L, aspartate aminotransferase at 2290 IU/L, alanine aminotransferase at 1224 IU/L, and bilirubin of 10.0 mg/dL with direct bilirubin of 7.4 mg/dL. The patient underwent interventional radiology transjugular liver biopsy demonstrating features of drug-induced liver injury secondary to pembrolizumab therapy. He was started on steroid therapy and completed six-week course with resolution in liver enzymes. This is a unique case in which pembrolizumab-induced hepatitis occurred three years after initiation of treatment. Due to the increased use of immune checkpoint inhibitors for oncologic treatment, it is important for clinicians to recognize their immune-related adverse effects and varying timing in which these toxicities may occur. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
